Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 26;4(11):e1027469. doi: 10.1080/2162402X.2015.1027469

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC

© Hanren Dai, Wenying Zhang, Xiaolei Li, Qingwang Han, Yelei Guo, Yajing Zhang, Yao Wang, Chunmeng Wang, Fengxia Shi, Yan Zhang, Meixia Chen, Kaichao Feng, Quanshun Wang, Hongli Zhu, Xiaobing Fu, Suxia Li, and Weidong Han

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 2. — Copy number of CAR molecules and CD19⁺ cells in the peripheral blood, bone marrow and Cerrebral spinal fluid. (A) Quantitative real-time PCR was performed on genomic DNA harvested from each patient's PBMCs collected before and at serial time points after CART-19 cell infusion, using primers specific for the transgene. CD19⁺ B cells expressed as count change from baseline in the blood after the infusion of CART-19 cells in all nine patients. Patients 2, 3, 4, 5, and 8 died before the last follow-up, the time of all patients after cell infusion range from 15 to 140 d. In all panels, ▴ indicates imatinib (TKI) therapy, ^↓ indicates the time of relapse, ^↑ indicates the time of second infusion, ^↓ indicates the time of chemotherapy, black squares represent the values for CAR copies by Q-PCR, and black circles indicate CD19⁺ B cell counts in PB. The first chemotherapy regimen: Cyclophosphamide Etoposide, Vincristine and Dexamethasone. The second chemotherapy regimen: Vincristine, Daunorubicin, Cyclophosphamide and Prednison (B, C) For patient Bone marrow and cerebralspinal fluid aspirates were obtained at serial time points after CART-19 cell infusion in patient 7. Black squares represent the values of CAR copies by Q-PCR and black circles indicate the detection of bcr/abl transcripts.

Inline graphic — Copy number of CAR molecules and CD19⁺ cells in the peripheral blood, bone marrow and Cerrebral spinal fluid. (A) Quantitative real-time PCR was performed on genomic DNA harvested from each patient's PBMCs collected before and at serial time points after CART-19 cell infusion, using primers specific for the transgene. CD19⁺ B cells expressed as count change from baseline in the blood after the infusion of CART-19 cells in all nine patients. Patients 2, 3, 4, 5, and 8 died before the last follow-up, the time of all patients after cell infusion range from 15 to 140 d. In all panels, ▴ indicates imatinib (TKI) therapy, ^↓ indicates the time of relapse, ^↑ indicates the time of second infusion, ^↓ indicates the time of chemotherapy, black squares represent the values for CAR copies by Q-PCR, and black circles indicate CD19⁺ B cell counts in PB. The first chemotherapy regimen: Cyclophosphamide Etoposide, Vincristine and Dexamethasone. The second chemotherapy regimen: Vincristine, Daunorubicin, Cyclophosphamide and Prednison (B, C) For patient Bone marrow and cerebralspinal fluid aspirates were obtained at serial time points after CART-19 cell infusion in patient 7. Black squares represent the values of CAR copies by Q-PCR and black circles indicate the detection of bcr/abl transcripts.